Park Circle Company’s Ginkgo Bioworks DNA Stock Holding History

Park Circle Company’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13	Closed	-$2K	–	113
2022 Q3	$2K	Hold	13	–	–	﹤0.01%	128
2022 Q2	$1K	Hold	13	–	–	﹤0.01%	134
2022 Q1	$2K	Hold	13	–	–	﹤0.01%	121
2021 Q4	$4K	Hold	13	–	–	﹤0.01%	124
2021 Q3	$6K	Buy	+13	New	+$6.33K	﹤0.01%	122

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Park Circle Company's DNA Position: Q4 2022 in Review

Park Circle Company sold out of Ginkgo Bioworks (DNA) in Q4 2022, closing a stake of 13 shares — an estimated $2K sold.

Park Circle Company first reported a position in DNA in Q3 2021 and held it in 5 quarters. The position peaked at $6K in Q3 2021. 320 funds tracked by Wall St. Rank hold DNA as of Q4 2022.

Park Circle Company reported no remaining Ginkgo Bioworks position as of Q4 2022 after selling out during the quarter.
Park Circle Company sold 13 Ginkgo Bioworks shares in Q4 2022, an estimated $2K.
Park Circle Company first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 5 quarters.
Park Circle Company's Ginkgo Bioworks position peaked at $6K in Q3 2021.
320 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2022.

Based on Park Circle Company's 13F filing for Q4 2022, filed 13 Feb 2023.